| NAME |
ZANUBRUTINIB 80MG CAP,ORAL |
| VA GENERIC NAME |
ZANUBRUTINIB |
| DOSAGE FORM |
CAP,ORAL |
| HAZARDOUS TO DISPOSE |
NO |
| FORMULARY DESIGNATOR |
PA-F |
| FORMULARY DESIGNATOR TEXT |
zanubrutinib is a BTK inhibitor approved for the treatment of mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinemia
|
| ACTIVE INGREDIENTS |
|
| NATIONAL FORMULARY INDICATOR |
YES |
| CS FEDERAL SCHEDULE |
Unscheduled |
| STRENGTH |
80 |
| SINGLE/MULTI SOURCE PRODUCT |
Single source |
| UNITS |
MG |
| NATIONAL FORMULARY NAME |
ZANUBRUTINIB CAP,ORAL |
| CREATE DEFAULT POSSIBLE DOSAGE |
YES |
| CODING SYSTEM |
|
| COPAY TIER |
-
- COPAY TIER LEVEL: 3
- COPAY EFFECTIVE DATE: 2019-12-02 00:00:00
|
| PGX ELIGIBLE |
NO |
| PGX SUPPRESSED |
NO |
| VA PRINT NAME |
ZANUBRUTINIB 80MG ORAL CAP |
| VA PRODUCT IDENTIFIER |
Z0119 |
| TRANSMIT TO CMOP |
YES |
| VA DISPENSE UNIT |
CAP |
| MASTER ENTRY FOR VUID |
YES |
| VUID |
4038979 |
| EFFECTIVE DATE/TIME |
-
- 2019-12-02 00:00:00
- STATUS: ACTIVE
|
